Ocular Therapeutix (OCUL) Finished Goods (2014 - 2026)

Ocular Therapeutix has reported Finished Goods for 13 years, with the latest figure at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Finished Goods rose 72.91% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (up 72.91% YoY), and the FY2025 full-year result was $1.6 million, up 22.74% from the prior year.
• Finished Goods for Q1 2026 stood at $2.2 million, up from $1.6 million in the prior quarter.
• The five-year high for Finished Goods was $2.2 million in Q1 2026, with the low at $343000.0 in Q3 2022.
• Average Finished Goods over 5 years is $1.1 million, with a median of $1.2 million recorded in 2023.
• Year-over-year, Finished Goods jumped 198.05% in 2022 and dropped 20.45% in 2024.
• Tracing OCUL's Finished Goods over 5 years: stood at $766000.0 in 2022, then rose by 29.37% to $991000.0 in 2023, then jumped by 34.91% to $1.3 million in 2024, then rose by 22.74% to $1.6 million in 2025, then surged by 34.55% to $2.2 million in 2026.
• The last three Finished Goods figures came in at $2.2 million (Q1 2026), $1.6 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.

Peer Comparison